nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

27.04.2018 | Review Article

Clinical utility of FDG-PET for the clinical diagnosis in MCI

verfasst von: Javier Arbizu, Cristina Festari, Daniele Altomare, Zuzana Walker, Femke Bouwman, Jasmine Rivolta, Stefania Orini, Henryk Barthel, Federica Agosta, Alexander Drzezga, Peter Nestor, Marina Boccardi, Giovanni Battista Frisoni, Flavio Nobili, for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aim to report the quality of accuracy studies investigating the utility of [¹⁸F]fluorodeoxyglucose (FDG)-PET in supporting the diagnosis of prodromal Alzheimer’s Disease (AD), frontotemporal lobar degeneration (FTLD) and prodromal dementia with Lewy bodies (DLB) in mild cognitive impairment (MCI) subjects, and the corresponding recommendations made by a panel of experts.

Methods

Seven panellist, four from the European Association of Nuclear Medicine, and three from the European Academy of Neurology, produced recommendations taking into consideration the incremental value of FDG-PET, as added on clinical-neuropsychological examination, to ascertain the aetiology of MCI (AD, FTLD or DLB). A literature search using harmonized population, intervention, comparison, and outcome (PICO) strings was performed, and an evidence assessment consistent with the European Federation of Neurological Societies guidance was provided. The consensual recommendation was achieved based on Delphi rounds.

Results

Fifty-four papers reported the comparison of interest. The selected papers allowed the identification of FDG patterns that characterized MCI due to AD, FTLD and DLB. While clinical outcome studies supporting the diagnosis of MCI due to AD showed varying accuracies (ranging from 58 to 100%) and varying areas under the receiver-operator characteristic curves (0.66 to 0.97), no respective data were identified for MCI due to FTLD or for MCI due to DLB. However, the high negative predictive value of FDG-PET and the existence of different disease-specific patterns of hypometabolism support the consensus recommendations for the clinical use of this imaging technique in MCI subjects.

Conclusions

FDG-PET has clinical utility on a fair level of evidence in detecting MCI due to AD. Although promising also in detecting MCI due to FTLD and MCI due to DLB, more research is needed to ultimately judge the clinical utility of FDG-PET in these entities.

Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease: implications for early diagnosis and treatment. Arch Gerontol Geriatr. 2011;52:18–22. https://doi.org/10.1016/j.archger.2009.11.004.CrossRefPubMed

Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72:599–609. https://doi.org/10.1002/ana.23654.CrossRefPubMedPubMedCentral

Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83. https://doi.org/10.1016/j.neurobiolaging.2010.04.007.CrossRefPubMed

Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017;16:661–76. https://doi.org/10.1016/S1474-4422(17)30159-X.CrossRefPubMed

Borroni B, Cosseddu M, Pilotto A, Premi E, Archetti S, Gasparotti R, et al. Early stage of behavioral variant frontotemporal dementia: clinical and neuroimaging correlates. Neurobiol Aging. 2015;36:3108–15. https://doi.org/10.1016/j.neurobiolaging.2015.07.019.CrossRefPubMed

Rogalski EJ, Mesulam MM. Clinical trajectories and biological features of primary progressive aphasia (PPA). Curr Alzheimer Res. 2009;6:331–6.CrossRefPubMedPubMedCentral

Boccardi M, Festari C, Altomare D, Gandolfo F, Orini S, Nobili F, et al. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4024-1.CrossRefPubMed

Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol. 2013;20:410–9. https://doi.org/10.1111/ene.12043.CrossRefPubMed

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.CrossRefPubMed

10.

McKhann GM, Jack CR, Albert MS, Knopman DS, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62. https://doi.org/10.1016/j.jalz.2011.03.004.CrossRefPubMedPubMedCentral

11.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–27. https://doi.org/10.1016/S1474-4422(10)70223-4.CrossRefPubMed

12.

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323. https://doi.org/10.1016/j.jalz.2016.02.002.CrossRefPubMedPubMedCentral

13.

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77. https://doi.org/10.1093/brain/awr179.CrossRefPubMedPubMedCentral

14.

Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.CrossRefPubMed

15.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49:390–8. https://doi.org/10.2967/jnumed.107.045385.CrossRefPubMed

16.

Lowe VJ, Kemp BJ, Jack CR, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878–86. https://doi.org/10.2967/jnumed.108.058529.CrossRefPubMed

17.

Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). NeuroImage. 2009;45:1107–16. https://doi.org/10.1016/j.neuroimage.2008.12.072.CrossRefPubMed

18.

Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary metrics to assess Alzheimer disease-related Hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012;53:592–600. https://doi.org/10.2967/jnumed.111.094946.CrossRefPubMed

19.

Kim SH, Seo SW, Yoon DS, Chin J, Lee BH, Cheong HK, et al. Comparison of neuropsychological and fdg-pet findings between early- versus late-onset mild cognitive impairment: a five-year longitudinal study. Dement Geriatr Cogn Disord. 2010;29:213–23. https://doi.org/10.1159/000278422.CrossRefPubMed

20.

Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, et al. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer’s disease. J Nucl Med. 2007;48:1129–34. https://doi.org/10.2967/jnumed.107.040675.CrossRefPubMed

21.

Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, et al. Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease. Brain Imaging Behav. 2012;6:568–83. https://doi.org/10.1007/s11682-012-9208-x.CrossRefPubMedPubMedCentral

22.

Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18. https://doi.org/10.1016/j.neurobiolaging.2009.07.002.CrossRefPubMed

23.

Nobili F, Mazzei D, Dessi B, Morbelli S, Brugnolo A, Barbieri P, et al. Unawareness of memory deficit in amnestic MCI: FDG-PET findings. J Alzheimers Dis. 2010;22:993–1003. https://doi.org/10.3233/JAD-2010-100423.CrossRefPubMed

24.

Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni GB, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer’s disease from healthy controls. A European Alzheimer’s disease consortium (EADC) study. NeuroImage Clin. 2015;7:34–42. https://doi.org/10.1016/j.nicl.2014.11.007.CrossRefPubMed

25.

Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80:1048–56. https://doi.org/10.1212/WNL.0b013e3182872830.CrossRefPubMed

26.

Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;66:185–98. https://doi.org/10.1111/j.1742-1241.2011.02845.x.CrossRefPubMed

27.

Yuan Y, Gu Z-X, Wei W-S. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol. 2009;30:404–10. https://doi.org/10.3174/ajnr.A1357.CrossRefPubMedPubMedCentral

28.

Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, De Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487–500. https://doi.org/10.1212/WNL.0b013e31829d86e8.CrossRefPubMedPubMedCentral

29.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–13. https://doi.org/10.1007/s00259-003-1194-1.CrossRefPubMed

30.

Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, et al. Characterizing Alzheimer’s disease using a hypometabolic convergence index. NeuroImage. 2011;56:52–60. https://doi.org/10.1016/j.neuroimage.2011.01.049.CrossRefPubMed

31.

Garibotto V, Borroni B, Kalbe E, Herholz K, Salmon E, Holtoff V, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology. 2008;71:1342–9. https://doi.org/10.1212/01.wnl.0000327670.62378.c0.CrossRefPubMed

32.

Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36–45. https://doi.org/10.1007/s00259-009-1218-6.CrossRefPubMed

33.

Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, van Berckel BNM, et al. Resting metabolic connectivity in prodromal Alzheimer’s disease. A European Alzheimer disease consortium (EADC) project. Neurobiol Aging. 2012;33:2533–50. https://doi.org/10.1016/j.neurobiolaging.2012.01.005.CrossRefPubMed

34.

Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, et al. Principal component analysis of FDG PET in amnestic MCI. Eur J Nucl Med Mol Imaging. 2008;35:2191–202. https://doi.org/10.1007/s00259-008-0869-z.CrossRefPubMed

35.

Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A, et al. MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings. Curr Alzheimer Res. 2010;7:287–94.CrossRefPubMed

36.

Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86. https://doi.org/10.1002/ana.23650.CrossRefPubMedPubMedCentral

37.

Arbizu J, Prieto E, Martínez-Lage P, Martí-Climent JM, García-Granero M, Lamet I, et al. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia. Eur J Nucl Med Mol Imaging. 2013;40:1394–405. https://doi.org/10.1007/s00259-013-2458-z.CrossRefPubMed

38.

Cabral C, Morgado PM, Campos Costa D, Silveira M. Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages. Comput Biol Med. 2015;58:101–9. https://doi.org/10.1016/j.compbiomed.2015.01.003.CrossRefPubMed

39.

Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron J-C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology. 2003;60:1374–7. https://doi.org/10.1212/01.WNL.0000055847.17752.E6.CrossRefPubMed

40.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46:1625–32.PubMed

41.

Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D. Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer’s disease. NeuroImage. 2012;60:221–9. https://doi.org/10.1016/j.neuroimage.2011.12.071.CrossRefPubMed

42.

Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–26. https://doi.org/10.2967/jnumed.111.090902.CrossRefPubMed

43.

Ito K, Fukuyama H, Senda M, Ishii K, Maeda K, Yamamoto Y, et al. Prediction of outcomes in mild cognitive impairment by using 18F-FDG-PET: a multicenter study. J Alzheimers Dis. 2015;45:543–52. https://doi.org/10.3233/JAD-141338.CrossRefPubMed

44.

Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer’s disease consortium (EADC) project. J Alzheimers Dis. 2015;44:815–26. https://doi.org/10.3233/JAD-142229.CrossRefPubMed

45.

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332–40. https://doi.org/10.1212/01.WNL.0000147469.18313.3B.CrossRefPubMed

46.

Toussaint P-J, Perlbarg V, Bellec P, Desarnaud S, Lacomblez L, Doyon J, et al. Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer’s disease using conjoint univariate and independent component analyses. NeuroImage. 2012;63:936–46. https://doi.org/10.1016/j.neuroimage.2012.03.091.CrossRefPubMed

47.

Young J, Modat M, Cardoso MJ, Mendelson A, Cash D, Ourselin S. Accurate multimodal probabilistic prediction of conversion to Alzheimer’s disease in patients with mild cognitive impairment. NeuroImage Clin. 2013;2:735–45. https://doi.org/10.1016/j.nicl.2013.05.004.CrossRefPubMedPubMedCentral

48.

Choo IH, Ni R, Schöll M, Wall A, Almkvist O, Nordberg A. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer’s disease in mild cognitive impairment patients. J Alzheimers Dis. 2013;33:929–39. https://doi.org/10.3233/JAD-2012-121489.CrossRefPubMed

49.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–8. https://doi.org/10.1212/WNL.0b013e3181e8e8b8.CrossRefPubMedPubMedCentral

50.

Poljansky S, Ibach B, Hirschberger B, Männer P, Klünemann H, Hajak G, et al. A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci. 2011;261:433–46. https://doi.org/10.1007/s00406-010-0184-0.CrossRefPubMed

51.

Banzo I, Jiménez-Bonilla J, Ortega-Nava F, Quirce R, Martínez-Rodríguez I, de Arcocha-Torres M, et al. Amyloid imaging with 11C-PIB PET/CT and glucose metabolism with 18F-FDG PET/CT in a study on cognitive impairment in the clinical setting. Nucl Med Commun. 2014;35:238–44. https://doi.org/10.1097/MNM.0000000000000042.CrossRefPubMed

52.

Bergeron D, Beauregard J-M, Guimond J, Fortin M-P, Houde M, Poulin S, et al. Clinical impact of a second FDG-PET in atypical/unclear dementia syndromes. J Alzheimers Dis. 2016;49:695–705. https://doi.org/10.3233/JAD-150302.CrossRefPubMed

53.

Morbelli S, Ferrara M, Fiz F, Dessi B, Arnaldi D, Picco A, et al. Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD. Eur J Nucl Med Mol Imaging. 2016;43:1337–47. https://doi.org/10.1007/s00259-016-3335-3.CrossRefPubMed

54.

Döbert N, Pantel J, Frölich L, Hamscho N, Menzel C, Grünwald F. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord. 2005;20:63–70. https://doi.org/10.1159/000085857.CrossRefPubMed

55.

Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 2014;6:445–54. https://doi.org/10.1016/j.nicl.2014.10.009.CrossRefPubMedPubMedCentral

56.

Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, et al. Visual versus fully automated analyses of 18F-FDG and amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment. J Nucl Med. 2016;57:204–7. https://doi.org/10.2967/jnumed.115.163717.CrossRefPubMed

57.

Cerami C, Della Rosa PA, Magnani G, Santangelo R, Marcone A, Cappa SF, et al. Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. NeuroImage Clin. 2015;7:187–94. https://doi.org/10.1016/j.nicl.2014.12.004.CrossRefPubMed

58.

Fujishiro H, Iseki E, Kasanuki K, Murayama N, Ota K, Suzuki M, et al. Glucose hypometabolism in primary visual cortex is commonly associated with clinical features of dementia with Lewy bodies regardless of cognitive conditions. Int J Geriatr Psychiatry. 2012;27:1138–46. https://doi.org/10.1002/gps.2836.CrossRefPubMed

59.

Perani D, Cerami C, Caminiti SP, Santangelo R, Coppi E, Ferrari L, et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging. 2016;43:499–508. https://doi.org/10.1007/s00259-015-3170-y.CrossRefPubMed

60.

Fujishiro H, Iseki E, Murayama N, Yamamoto R, Higashi S, Kasanuki K, et al. Diffuse occipital hypometabolism on [18 F]-FDG PET scans in patients with idiopathic REM sleep behavior disorder: prodromal dementia with Lewy bodies? Psychogeriatrics. 2010;10:144–52. https://doi.org/10.1111/j.1479-8301.2010.00325.x.CrossRefPubMed

61.

Fujishiro H, Iseki E, Kasanuki K, Chiba Y, Ota K, Murayama N, et al. A follow up study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies. J Neurol Sci. 2013;334:48–54. https://doi.org/10.1016/j.jns.2013.07.013.CrossRefPubMed

62.

Pardo JV, Lee JT, Kuskowski MA, Munch KR, Carlis JV, Sheikh SA, et al. Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years. Alzheimers Dement. 2010;6:326–33. https://doi.org/10.1016/j.jalz.2009.09.005.CrossRefPubMedPubMedCentral

63.

Clerici F, Del Sole A, Chiti A, Maggiore L, Lecchi M, Pomati S, et al. Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q J Nucl Med Mol Imaging. 2009;53:646–57.PubMed

64.

Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36:811–22. https://doi.org/10.1007/s00259-008-1039-z.CrossRefPubMedPubMedCentral

65.

Perani D, Daniela P, Schillaci O, Orazio S, Padovani A, Alessandro P, et al. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int. 2014;2014:785039. https://doi.org/10.1155/2014/785039.CrossRefPubMed

66.

Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. ¹⁸ F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1:CD010632. https://doi.org/10.1002/14651858.CD010632.pub2.CrossRefPubMed

67.

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, et al. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183–95. https://doi.org/10.1016/j.neurobiolaging.2016.03.033.CrossRefPubMed

68.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. https://doi.org/10.1016/S1474-4422(14)70090-0.CrossRefPubMed

69.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. https://doi.org/10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentral

70.

Gossink FT, Dols A, Kerssens CJ, Krudop WA, Kerklaan BJ, Scheltens P, et al. Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2016;87:64–8. https://doi.org/10.1136/jnnp-2014-308284.CrossRefPubMed

71.

Kipps CM, Hodges JR, Fryer TD, Nestor PJ. Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: refining the clinical phenotype. Brain. 2009;132:2566–78. https://doi.org/10.1093/brain/awp077.CrossRefPubMed

72.

Nestor P, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4035-y.CrossRefPubMed

73.

Nobili F, Festari C, Altomare D, Agosta F, Orini S, Van Laere K, et al. Automated assessment of FDG-PET for the differential diagnosis in patients with neurodegenerative disorders. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4030-3.CrossRefPubMed

Titel: Clinical utility of FDG-PET for the clinical diagnosis in MCI
verfasst von: Javier Arbizu
Cristina Festari
Daniele Altomare
Zuzana Walker
Femke Bouwman
Jasmine Rivolta
Stefania Orini
Henryk Barthel
Federica Agosta
Alexander Drzezga
Peter Nestor
Marina Boccardi
Giovanni Battista Frisoni
Flavio Nobili
for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Publikationsdatum: 27.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4039-7

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease

18F-FDG PET and high-resolution MRI co-registration for pre-surgical evaluation of patients with conventional MRI-negative refractory extra-temporal lobe epilepsy

Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage